Novel Pharmaceutical Novels & Stories

Alora’s POV I had finally scored an interview with a pharmaceutical company called NovaMeds Research Group, a medical research firm focused on regenerative medicine that bordered on cutting-edge science and ancient healing traditions. It was a long-standing company known for making breakthroughs in cellular regeneration and rare disease treatment, and that was the perfect place for me to jumpstart my career. I figured working as an intern in the company would give me enough flexibility to run my programme, learn from experienced hands, and grow in the field.

Trish and Lilian were with them as well. Trish got the medication and glanced at it. "This is the heart medication NovaHealth just released. It's incredibly effective, and it's been all the rage in the medical community." "Who developed this heart medication?" Jessica asked. "The founder of NovaHealth, who registered NovaHealth as a naturopathy brand six years ago. Not only do NovaHealth hospitals have a presence all over the place, but the company also went public as a large pharmaceutical company overseas six years ago. It shocked the entire medical world," Trish explained.

When the outside world learned that The Apothecary Pharmaceutical had a new drug and a new health product that was about to be launched into the market, almost everyone awaited the official release of these two products eagerly. This was because in their opinion, if The Apothecary Pharmaceutical could develop a special drug for cancer and the Apothecary Stomach Pill was also extremely good on its own, the level of the other products that it released naturally would not be too bad either and might even be amongst the best.

Chris, who had never proactively accepted any invitation before, felt a bit puzzled. He looked up at Francesca beside him. Francesca quickly gave him a simple explanation. “Wind Pharmaceuticals has always ranked among the top three in the domestic pharmaceutical industry. Especially this time, the new drug being launched is a special medicine targeting cardiovascular diseases. The News Guide had already posted trial data showing a relief rate as high as 56%. Within this category of drugs, that relief rate was considered very high. No hospital yet had obtained the rights to use the new drug. Apart from public hospitals which don’t need to compete, all major private hospitals would participate